Efficacy and safety of single-inhaler triple therapy of glycopyrronium, formoterol and fluticasone in patients with COPD: a double-blind, randomised controlled trial

Efficacy and safety of single-inhaler triple therapy of glycopyrronium, formoterol and fluticasone in patients with COPD: a double-blind, randomised controlled trial

Background The aim of this work was to investigate the safety and efficacy of single-inhaler triple therapy with 12.5 g glycopyrronium (GB)/12 g formoterol fumarate (FF)/250 g fluticasone propionate (FP), compared to 50 g GB co-administered with a fixed dose of 12 g FF/250 g FP in subjects with COPD...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:ERJ open research 2021-07, Vol.7 (3), p.255, Article 00255
Hauptverfasser: Salvi, Sundeep, Balki, Akash, Krishnamurthy, Srikanth, Panchal, Sagar, Patil, Saiprasad, Kodgule, Rahul, Khandagale, Hitesh, Pendse, Amol, Wu, Wen, Rangwala, Shabbir, Tandon, Monika, Barkate, Hanmant
Format: Artikel
Sprache:eng
Schlagworte:
Life Sciences & Biomedicine
Original s
Respiratory System
Science & Technology
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Background The aim of this work was to investigate the safety and efficacy of single-inhaler triple therapy with 12.5 g glycopyrronium (GB)/12 g formoterol fumarate (FF)/250 g fluticasone propionate (FP), compared to 50 g GB co-administered with a fixed dose of 12 g FF/250 g FP in subjects with COPD. Methods This was a phase 3, randomised, double-blind, active-control, parallel-group, noninferiority study conducted at 20 sites across India. COPD patients aged >= 40 to
ISSN:2312-0541
2312-0541
DOI:10.1183/23120541.00255-2021